ARTHROASPIS FIX
PRODUCT INFORMATION
Arthroaspis fix is a food supplement with ingredients that help to manage symptoms of Chondropathy. Its ingredients help to reduce pain and stiffness, as well as to slow the progression of the disease. They act as a joint lubricant, relieving joint pain.
The product includes Undenaturated Type-II Collagen with high oral tolerance that helps to protect cartilage through its anti-inflammatory properties. Boswellia serrata extract is another ingredient of Arthroaspis fix, with high anti-inflammatory properties, that provide pain relief and reduction of swelling in patients.
Arthroaspis fix, also includes Astaxanthin, the strongest natural antioxidant, that protects from oxidative damage and regulates the inflammation status, apparent during Chondropathy.
Finally, it includes Vitamins D3 & K2 that contribute to the maintenance of normal bones.
*Health claims according to (EU) Regulation 432/2012: Vitamin D contributes to the maintenance of normal bones
ADVANTAGES
Arthroaspis fix includes ingredients that act in synergy and help to:
- Prevent from oxidative stress
- Reduce inflammation
- Enhances joint health
- Manages pain and stiffness
- Improves fatigue symptoms
- Slows down the progression of Osteoarthritis
INDICATIONS
Arthroaspis fix based on its formulation, is addressed to patients with:
- Chondropathy
- Preventive use
RECOMMENDED DOSAGE
1 tablet per day for 3 months
CHARACTERISTICS
- 100% Natural Product
- Formulation based on clinical studies
- Ingredients with high antioxidant and anti-inflammatory action
- Bioactive collagen resistant to gastric acids
- Compatible with medication
- No Side Effects
- No GMOs
- No sugar
- Gluten free
Commercial rights & brand holder: Aniva International S.A.
Food supplements should not be used as a substitute of a well-balanced diet. This product is not intended to prevent, treat or cure any human disease. If you are pregnant, nursing, taking medication, or have medical condition, consult your physician before using this product. Keep out of reach of children.
Notification number National Agency of Medicine, Greece : 91498 / 24-7-2024